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Abstract
While there have been many reports investigating the biological activity and signaling mechanisms of isoprostanes, 
their role in biology, particularly in platelets, appears to still be underestimated. Moreover, whether these lipids have 
their own receptors is still debated, despite multiple reports that discrete receptors for isporpstanes do exist on 
platelets, vascular tissues, amongst others. This paper provides a review of the important literature of isoprostanes and 
provides reasoning that isoprostanes should be classified as orphan ligands until their receptor(s) is/are identified.
Review
Maintaining proper function of platelets is vital as their
primary task is to stop bleeding from an injured vessel, a
process known as hemostasis [1,2]. The hemostatic plug
that forms in order to halt blood loss must be capable of
rapid dissolution upon wound healing [3]. Nonetheless,
blood flow must remain unimpeded in all other instances
to ensure effective nutrient and waste exchange. Thus,
platelets are, necessarily, firmly regulated blood elements
that must be highly and quickly responsive to activating
stimuli but otherwise are "completely" quiescent. Mal-
functions in either of these behaviors leads to a host of
disorders [3,4]. Furthermore, various deficiencies in acti-
vation result in bleeding diseases which are associated
with morbidity and mortality and may require lifetime
treatment (e.g., von Willebrand disease) [4,5]. Conversely,
improper activation, or recruitment of platelets to sites
where hemostasis is not needed are hallmarks of myocar-
dial infarction, ischemic stroke, peripheral artery disease
and other thrombotic ailments that together represent a
major source of mortality [6]. Thus, the mechanism of
platelet regulation and more specifically, their activation
is of great interest as understanding these signaling path-
ways will allow for the development of specific and ratio-
nally developed therapeutic intervention strategies.
Platelets are the second most abundant cells of the
blood numbering hundreds of millions per milliliter of
whole blood [7]. Yet, this still only comprises a very small
fraction of blood volume, as they are individually minus-
cule. This derives from the fact that platelets are not
themselves "true" cells but are merely cellular fragments
[8]. Thus, they lack nuclei; which makes certain modifica-
tions to their signaling or effector molecules irreversible
(e.g. nonspecific cyclooxygenase inhibition when plate-
lets are exposed to aspirin) [9]. Platelet function returns
only upon replacement with newly synthesized cells. To
this end, platelets are produced in the bone marrow and
are derived from very large cells called megakaryocytes
[10]. As megakaryocytes develop, they undergo a bud-
ding process that results in the release of several thou-
sand platelets per megakaryocyte allowing for rapid
replenishment in the absence of faults in platelet regula-
tion [8,10].
Platelet Activation
While a platelet lacks several organelles that are present
in other cell systems, it possesses complex structures that
are essential for its central role in hemostasis; which can
be inappropriately marshaled in thrombosis-based
events. Platelets are normally smooth and discoid in
shape, hence their name [11]. If platelets are stimulated
by one of a group of agonists (thrombin, thromboxane A2
(TXA2), ADP, etc) they initiate and undergo a sequence of
physiological and anatomical changes [1,11-15]. The first
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discernible sign of platelet activation is shape change (i.e.,
platelets become spherical), and is associated with the
extension of long pseudopodia [16]. This is due to an ele-
vation in actin and myosin to levels that are only
exceeded by muscle cells and is initiated by increases in
cytosolic calcium (Ca2+) that results in phosphorylation
o f  m yos in li gh t  c hai n by a  Ca 2+-calmodulin-dependent
kinase, which in turn enhances myosin binding of actin
[1,17]. In fact, experimentally induced activation can be
achieved through exposure to Ca2+ ionophores in addi-
tion to physiological agonists and/or their derivatives
[18].
Platelets also express adhesive proteins on their surface
that allows them to adhere to the exposed subendothe-
lium in a injured blood vessel, as well as to surface pro-
teins of nearby platelets [2,11]. Therefore, the next phase
of activation is characterized by adhesion and aggrega-
tion of platelets as they bind to the damaged tissue as well
as each other, thereby preventing further blood loss from
a wound. In addition, platelets contain several types of
intercellular granules (i.e., alpha and dense granules) [19].
Alpha granules contain growth factors (such as platelet-
derived growth factor, insulin-like growth factor-1, tissue
growth factor-β, and platelet factor-4), the adhesion mol-
ecule, P-selectin, and clotting proteins (such as thrombo-
spondin, fibronectin, and von Willebrand factor) [20].
Dense granules contain platelet agonists such as adenine
nucleotides (ADP), ionized Ca2+, and signaling molecules
(such as histamine, serotonin, and epinephrine) [21,22].
Secretion is considered the next stage of platelet activa-
tion, as these chemicals play an essential role in the
hemostatic process as they serve to amplify platelet
response [13]. Due to this exponential activation, many of
these steps overlap among a population of platelets.
Hence, aggregation is reinforced by the secreted fibrino-
gen and thrombospondin, further binding the platelets
together, as well as by the dense granule-secreted agonists
which can signal further secretion (thus providing a
strong positive feedback loop). These substances are
thought to potentiate each others' effects. Finally, actin
and myosin mediate platelet retraction as activated plate-
lets condense the loose clot formed previously to seal a
vascular wound into a hard, dense mass capable of resist-
ing dispersion until wound healing is complete [23].
Platelet Signaling
Central to platelet activation is the mobilization of Ca2+
from stores within the platelet that then signals additional
Ca2+ entry into the cell from the extracellular environ-
ment. In this connection, the Ca2+ ionophore A23187
mediates platelet shape change, aggregation, and secre-
tion, essentially acting identically to other platelet ago-
nists [18]. The particular temporal arrangement of
platelet activation is believed to be a result of increasing
concentrations of Ca2+ and possibly other intracellular
signaling transmitters. The responses appear to be chron-
ological, but this is not due to any prerequisites of a previ-
ous stage but because of the order of their dependence on
Ca2+  concentration [1,24]. Thus, since shape change
requires the least Ca2+ concentrations to trigger, it's the
most difficult to inhibit. On the other hand, secretion and
aggregation require greater Ca2+  concentrations, and,
consequently, are more readily inhibited. The signaling
pathways controlling the initiation or the amplification of
intracellular Ca2+ entry are thus of major interest in plate-
let biology. While there are a host of additional effectors,
comprised of G-proteins, MAP Kinases, and other mole-
cules, these all integrate at the level of activating the
GPIIb/IIIa on platelet surface [25]. When platelets are
activated, this adhesive molecule undergoes a conforma-
tional change so that it can recognize fibrinogen mole-
cules, which allows for the formation of platelet
aggregates [16,25].
Platelets are activated through several signaling modal-
ities. Aggregation initiates within seconds upon exposure
to ADP, thrombin, serotonin, and epinephrine. Thrombin
is considered the most potent physiologic agonist and
thus has been widely used to study secretion along with
arachidonic acid (AA), endoperoxides, or TXA2 (Figure 1)
as they can induces platelet shape change, aggregation,
and secretion [26]. In contrast, platelet stimulation by
epinephrine is not associated with change in platelet
shape [27]. Additionally, the effects of "low" concentra-
tion of collagen are thought to be dependent on arachido-
nate metabolism. Aggregation is usually required for
secretion as the dense packing and resultant decrease in
Figure 1 Structure of arachidonic acid (the precursor for all pros-
taglandins), various TPR ligands, PGF2α, and the most abundant 
isoprostane 8-iso-PGF2α.Ting and Khasawneh Journal of Biomedical Science 2010, 17:24
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interstitial spaces serves to concentrate otherwise low
levels of released AA metabolites [13,28]. One exception
to this requirement is thrombin as it can induce secretion
in nonaggregated suspensions [1]. Due to the presence of
numerous, biologically active metabolites, one critical
activation arm of platelets is dependent on AA. AA,
which is the most abundant, is a 20-carbon unsaturated
fatty acid [29]. The release of AA from the membrane by
phospholipases, and subsequent metabolic modifications
leads to the formation of well-characterized prostaglan-
dins and thromboxanes (Figure 2). Of primary impor-
tance to platelet function is the formation of TXA2, which
is generated from arachidonic acid in reaction catalyzed
by the platelet cyclooxygenase-1 enzyme [30]. Generated
TXA2  then binds to its G-protein coupled receptor
(GPCR) known as TXA2 receptor (abbreviated as TPR).
There are two splice variants for TPR with distinct tissue
expression, i.e., the placental α-isoform and the endothe-
lial β-isoform [31]. Interestingly, using isoform-specific
TPR antibodies, TPR-α but not TPR-β was immunopre-
cipitated from platelets [32]. Furthermore, consistent
with this finding, platelets were found to express high lev-
els of mRNA for the α-isoform and low levels of β-iso-
forms. Taken together, these data suggest a limited role, if
any, for the β-isoforms in platelet function.
Interaction of TXA2, or other agonists to their cognate
receptors, leads to transduction of activating signals into
secondary messengers. One major pathway for this
response is the GPCRs [29,33-35]. G-proteins, which
consist of three different subunits, α, β and γ, can be
divided into four major families, Gq, G12, Gi and Gs, of
which platelets have been found to express several dis-
tinct members [34,36]. More specifically, a host of in vitro
approaches involving reconstitution studies, affinity
copurification experiments or cross-linking studies with
photoactivated GTP analogs demonstrated that platelets
express Gq, G16 (Gq family), G12, G13 (G12 family), Gs, as
well as Go, Gi and Gz (Gi family) [33,35,37-41]. These
studies have specifically revealed that TPR couples to the
Gq and G13 isoforms. Additionally, U46619, a stable TXA2
mimetic, induces a rapid, transient rise in intracellular
Ca2+ in platelets and in HEK293 cells cotransfected with
Gαq or Gα11 and the α-isoform of TPR [42]. Further evi-
dence also indicates that the TPRα isoform can function-
ally couple to Gq or to G11 in vivo.
The G-protein, Gαq, signaling pathway starts by the
activation of phospholipase C (PLC) which in turn
metabolizes phosphatidylinositol 4,5-bisphosphate (PIP2)
into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG) [43,44]. IP3 then binds to its receptor and raises
cytosolic Ca2+ concentrations by inducing Ca2+ release
from vesicles into the cytoplasm [45,46]. DAG serves to
stimulate protein kinase C (PKC) which in turn activates
phospholipase A2 (PLA2) [47]. It is thought that both the
increase in cytoplasmic Ca2+ and the production of DAG
are necessary for full platelet activation, and lead to the
activation of the glycoprotein GPIIb/IIIa[48,49]. This GP
is a heterodimeric complex of two GPs on the platelet
surface that serves as the fibrinogen receptor [16,25].
Fibrinogen is a dimeric molecule that serves as a molecu-
lar bridge which crosslinks platelets, thereby enabling
platelet aggregation and formation of a primary hemo-
static plug [50]. On this basis, activation of GPIIb/IIIa is
absolutely critical for platelet function. Under in vitro set-
tings, the conformational change required for the forma-
tion of "active" GPIIb/IIIa requires calcium [48,49,51].
Taken together, it's believed that increases in intracellular
Ca2+ are the ultimate mediator of activation in platelets.
Arachidonic acid metabolites such as TXA2, have been
shown to trigger platelet responses dependent on stimu-
lation of G12/13-/Gq-coupled receptors [37,38,41,52]. Sig-
naling through these receptors has been shown to
enhance phosphorylation of several tyrosine kinase fami-
lies (Src, Syk and FAK) [53]. Consistent with the role of
G12/13-coupled receptors, low doses of U46619 was found
to trigger tyrosine phosphorylation of FAK, Syk and Src
[54]. Secretion of TXA2 (or other AA metabolites that act
though TPRs such as isoprostanes) from activated plate-
lets and other sources may then mediate further activa-
tion through this tyrosine-kinase-dependent signaling
pathway [55]. Additionally, thrombin has been reported
to induce phosphorylation of FAK in both platelets and
HEK293 cells, and binding of GPIIb/IIIa to fibrinogen ini-
tiates a second sustained wave of tyrosine phosphoryla-
tion [56,57]. In fact, GPCR-mediated activation of
tyrosine kinases is well characterized during integrin-
mediated assembly of cytoskeletal and signaling proteins
to focal adhesion sites [58]. Interestingly, U46619 medi-
ated activation was found to be independent of GPIIb/
IIIa binding to fibrinogen or the interaction of secreted
ADP with its platelet receptors (i.e., P2Y1 and/or P2Y12)
[54]. Signaling through this modality alone was insuffi-
cient to stimulate full platelet activation, but synergized
with the Gz-linked adrenaline receptor (epinephrine) to
mediate platelet aggregation [29,59,60]. In fact, it has
been reported that combined signaling via G12/13 and Gi is
required for full platelet activation [61,62]. Furthermore,
signaling through both the G12/13-dependent Rho-kinase,
and the tyrosine-kinase-dependent pathways was found
to be required for the synergistic activation of GPIIb/IIIa
[63]. Thus, these signals converge with additional signals
ensuing from the engagement of Gz-coupled receptors
[33,36]. Together, this data reveals that a combination of
agonists at subthreshold levels or with low potency canT ing and Khasawneh Journal of Biomedical Science 2010, 17:24
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serve to activate platelets in the absence of more potent
and perhaps more intentional activation.
Collectively, platelet TPRs are known to couple to the
four major families of G-proteins, which in turn activate
numerous downstream effectors, including second mes-
senger systems such as IP3/DAG, cAMP, small G proteins
(Ras, Rho, and Rac, effectors such as p160 ROCK, as well
as the Ca2+/calmodulin system) [33,34,36,64-67], phos-
phoinositide-3(PI3) kinase, activation of Syk, Src, and
FAK tyrosine kinase and mitogen-activated protein
kinase (MAPK, specifically p38 and p42) as well as pro-
tein kinase A and C (PKA and PKC) [54,65,68]. Addition-
ally, the action of many platelet agonists (ADP, thrombin,
low dose collagen) serves to mediate synthesis and subse-
Figure 2 A schematic representation of the arachidonic acid metabolism pathway. After its liberation by phospholipases, ((i.e., phospholipase 
A2 (PLA2) or phospholipase C (PLC)), the free arachidonic acid may undergo enzymatic metabolism by the lipoxygenases which produce HPETEs and 
leukotrienes, and the cyclooxygenases (COX-1, COX-2) which generate prostaglandins and thromboxanes. The specific repertoire of the arachidonic 
acid metabolites produced may vary according to the expression profile of these enzymes in different cell types. In platelets, for example, arachidonic 
acid is metabolized by COX-1 into the prostaglandin endoperoxides, PGG2 and PGH2. Next, thromboxane synthetase further metabolizes PGH2 into 
TXA2, which is a potent activator of platelet aggregation, with a half-life of 20-30 seconds. Thromboxane A2 is then hydrolyzed to the inactive form 
TXB2 (not shown). On the other hand, if PGH2 is metabolized by prostacyclin synthetase, then PGI2 would be produced (e.g., in endothelial cells). Fur-
thermore, if PGH2 is acted upon by PGD or PGE isomerase, then PGD2, and PGE2 are produced, respectively (e.g., in renal cells). Finally, if the PG re-
ductase metabolizes PGH2, then PGF2α is produced (e.g., pulmonary vessels). Thus, the biological functions of arachidonic acid are exerted indirectly 
after its metabolism into prostaglandin and thromboxane metabolites.Ting and Khasawneh Journal of Biomedical Science 2010, 17:24
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quent secretion of TXA2 [1,49,63]. Thus, TXA2 is not only
a potent direct activator of platelet function, it is also a
key effector in other agonist mediated pathways. Fortu-
nately, TXA2 is also highly unstable (a half life of around
30 seconds) and functions primarily as an autocrine or
local paracrine signal allowing for tight spatial regulation
of platelet activation [69]. The discovery of this central
role for AA metabolite pharmacological activity has
motivated the design of drugs with TPR antagonistic
activity.
Isoprostanes
While research on arachidonic acid metabolites have
focused on the traditional enzyme mediated pathway,
there is another potential route for arachidonic acid mod-
ification, i.e., a free radical mediated pathway [70,71].
This metabolic cascade has led to the investigation of a
class of "naturally" occurring prostaglandin-like products
known as isoprostanes. These are produced by the free
radical mediated oxidation of unsaturated fatty acids (Fig-
ure 3) in membrane phospholipids as opposed to the
enzymatically catalyzed oxidation found with the classi-
cal AA derivatives such as TXA2 [70,72]. As the forma-
tion of isoprostanes is not enzymatically-directed, but
random chemical degradation, there is a larger variety of
molecules produced in vivo (Figure 3). Whereas the
endoperoxide prostaglandin G2  (PGG2) is specifically
f o r m e d  b y  t h e  c y c l o o x y g e n a s e  e n z y m e s  ( C O X - 1  a n d
COX-2), four classes of isoprostanes are produced as a
result of the free-radical oxidation of AA (Figure 3), with
each class containing 16 subtypes of isoprostanes result-
ing in 64 individual isoprostane molecules [73].
Due to their interesting chemical properties and large
number of distinct members, isoprostanes are of clinical
interest for two main reasons: 1. they are ligands for pros-
taglandin receptors, and thus may exhibit biological
activity like TXA2 and other AA metabolites [70,74]; and
2. they have been found to associate with the oxidative
status of an organism [75,76]. Moreover, there is evidence
that their levels serve as a predictor of the onset and
severity of inflammatory diseases such as atherosclerosis
and Alzheimer's disease [75,77]. Indeed, isoprostanes are
thought to participate in the pathogenesis of Alzheimer's
disease. Evaluation of the blood and urinary levels of cer-
tain isoprostanes' and their metabolites, respectively, has
been demonstrated to be a reliable approach to the
assessment of lipid peroxidation, and therefore of oxida-
tive stress in vivo [78]. More specifically, evidence points
to the possibility that isoprostanes may be involved in the
genesis of certain disease states. For example, in vitro
Figure 3 A schematic representation of the metabolic cascade for the non-enzymatic generation of isoprostanes. This is a proposed scheme 
in which four series of regioisomers of PGG2 are formed, before they are reduced to PGF2α isomers. As shown, isoprostanes can be formed from arachi-
donic acid in situ in phospholipids, from which they are presumably cleaved by phospholipases A2. PGG2 spontaneously rearranges to PGD2 and PGE2 
thereby generating isoprostanes of the D and E series. The initial step in the formation of an isoprostane from arachidonic acid (I) is the generation of 
a lipid free radical by the abstraction of a hydrogen atom from one of the three methylene-interrupted carbon atoms, C7, C10, or C13, as shown here, 
by a free radical (FR•) which may be a hydroxyl radical (HO•), a superoxide radical (O2
-•) or other free radical, and results in (II). Radical attack at C-10 is 
shown, abstraction at the other positions determines the relative proportion of the isomers formed. The lipid free radical is converted to a peroxy rad-
ical by reaction with molecular oxygen. The peroxy radical cyclizes in an intramolecular reaction that yields an endoperoxide (III). The free radical chain 
reaction will continue to propagate until quenched by an antioxidant.Ting and Khasawneh Journal of Biomedical Science 2010, 17:24
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studies revealed that isoprostanes can induce oligoden-
drocyte progenitor cell death and induce vasoconstric-
tion and mitogenesis, as well as inflame endothelial cells
to bind monocytes, a critical initiating event in athero-
genesis [79-81]. An in vivo mouse model suggested that
isoprostanes are involved in the development of thrombi
at sites of vascular injury [82]. Furthermore, LDLR- and
ApoE-deficient mouse models demonstrated that these
oxidation products accelerate the development of athero-
sclerosis independent of de novo TXA2  synthesis or
changes in plasma lipid levels [83]. In patients with ath-
erosclerosis and acute myocardial infarction, levels of iso-
p r o s t a n e s  w e r e  a l s o  f o u n d  t o  b e  e l e v a t e d  a n d  t h e i r
reduction coincided with decreased atherogenesis, sug-
gesting a role for this oxidized lipid in the development of
this disease state [76,84].
Most of the studies examining the biological activity of
isoprostanes have been conducted with a specific form,
8-iso-PGF2α (Figure 1), as it is one of the most abundantly
produced in vivo [85]. Much work has been done with
this compound as it is commercially available, having
been previously synthesized for unrelated reasons and
was therefore readily available for a host of studies (i.e.,
infusion, bioassay, receptor binding/affinity studies, etc).
Additionally, it exhibits chemical stability that signifi-
cantly exceeds that of TXA2, suggesting it's potential for
long-term signaling capacity that may lead to systemic
priming of platelets [83]. To this end, 8-iso-PGF2α has
been reported to exhibit significant biological activity.
Specifically, it has been found to be a mitogen in 3T3 cells
and in vascular smooth muscle cells and evidence sug-
gests it may play a role in pulmonary oxygen toxicity
[86,87]. This biological activity may be a result of modifi-
cation of the integrity and fluidity of membranes, a char-
acteristic consequence of oxidative damage [88]. This
occurs as a result of the distorted shape of isoprostanes
relative to the normal fatty acids present in membrane
phospholipids and could be critical in modifying the
hemodynamic properties in vascular tissues into a more
dysfunctional microenvironment conducive to initiating
chronic disease states.
Isoprostane Signaling Pathways
Given the plethora of reports that suggest 8-iso-PGF2α
exerts biological actions on platelets, elucidating the con-
centrations necessary to elicit these effects and reconcil-
ing these with the levels reported to circulate in vivo is of
relevance to investigating its underlying mechanism of
action. In pursuit of this goal, it was found that there is a
minimum threshold concentration of 8-iso-PGF2α  at
which it has the capacity to induce platelet shape change
and above which it can alter the formation of thrombox-
ane or irreversible aggregation in response to platelet
agonists [89,90]. Additionally, 8-iso-PGF2α synergistically
mediates aggregation upon exposure to subthreshold
concentrations of platelet agonists [74]. Such a modality
is supported by findings that when epinephrine and AA
were added to platelet rich plasma (PRP) in subthreshold
concentrations, they acted in a synergistic manner to pro-
duce platelet aggregation[29]. This synergistic platelet
activation in response to dual exposure to 8-iso-PGF 2α
and other agonists would be most likely in settings where
platelet activation and enhanced free radical formation
(and thus isoprostane formation) coincide, a characteris-
tic microenvironment of atherosclerosis. This synergism
was found to be abrogated by calcium channel inhibitors,
an α2-receptor antagonist and inhibitors of PLC, MAP
kinase, and COX pathways [29]. Since increased cytosolic
Ca2+  is essential to platelet activation, the proposed
mechanism for potentiation between platelet agonists is
the activation of the Ca2+ signaling cascade. Thus, a rise
in cytosolic Ca2+ levels induced by the first agonist primes
platelets for an enhanced functional response to a second
agonist. In accord with this possible mechanism, increas-
ing concentrations of 8-iso-PGF2α  resulted in dose-
dependent, irreversible platelet aggregation in the pres-
ence of subthreshold concentrations of collagen, ADP,
AA, and analogs of TXA2 (i.e., I-BOP, U46619)[74]. This
phenomenon was not evident when platelets were pre-
treated with either COX inhibitors or TPR antagonists,
indicating a clear dependence of aggregation on the sec-
ondary formation of TXA2. Interestingly, 8-iso PGF2α
failed to desensitize the calcium or inositol phosphate
responses to platelet stimulation by these agonists. Fur-
thermore, 8-iso-PGF3α a related chemical to 8-iso-PGF2α
failed to initiate platelet shape change or aggregation nor
did it raise intracellular calcium or inositol phosphates,
suggesting a structural requirement for engaging the
receptor's ligand binding domain(s).
In the course of characterizing the properties of iso-
prostanes, it was discovered that they exert their biologi-
cal activity on a host of cell types: platelets, kidney, and
others, presumably via the activation of TPR [80,91,92]. It
has previously been shown that 8-iso-PGF2α  induces
intracellular Ca2+  mobilization in cells co-transfected
with TPRα and Gαq or Gα11 [42]. More specifically, co-
transfection of Gα11  produced greater mobilization of
intracellular Ca2+ than that stim ula ted by G αq. Surpris-
ingly, in human platelets, 8-iso PGF2α failed to cause a
dose-dependent increase in TPRα  phosphorylation, in
spite of stimulating inositol phosphate formation [32]. It
i s  po s s i b l e  t h a t  t h e  ca p a c i t y  o f  8 - i s o - PG F 2α for  in vivo
platelet activation manifests only if it's delivered through
an especially concentrated mechanism, such as from
microvesicles shed by activated cells, or through selectiveTing and Khasawneh Journal of Biomedical Science 2010, 17:24
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reincorporation of secreted isoprostanes into the mem-
brane[93]. Nevertheless, this explanation is only partially
satisfactory since the TXA2 mimetic U46619, but not 8-
iso-PGF2α, reduced glomerular insulin space and
increased inositol 1,4,5-trisphosphate production in rat
glomeruli and mesangial cells in a an apparently TPR-
dependent fashion (i.e., blocked by the TPR antagonist
SQ29,548)[91]. Conversely, rat aortic smooth muscle cells
were found to possess specific binding sites for both
TXA2  and 8-iso-PGF2α  and displayed functional
responses to both agonists, such as time- and dose-
dependent activation of MAP kinases [74,91]. Interest-
ingly, the addition of 8-iso-PGF2α and U46619 together
did not potentiate or antagonize the maximal level of
Ca2+ mobilized in either platelets or transfected HEK293
cells, which suggests that 8-iso-PGF2α and U46619 are
acting through the same pathway (TPR) [42]. In line with
this notion, SQ29,548 was found to be equally potent in
abolishing the Ca2+ response in both platelets and trans-
fected HEK293 cells upon stimulation with either U46619
or 8-iso-PGF2α. Pretreatment of platelets or transfected
cells with thrombin, on the other hand, did not desensi-
tize the rise in intracellular Ca2+ upon subsequent stimu-
lation with either U46619 or 8-iso-PGF2α, which provides
further evidence that these lipids share a common signal-
ing pathway, though previous work showing abrogation
of effect by 8-iso-PGF2α in the presence of COX inhibitors
suggests that formation of TXA2 is the potential link at
the TPR modality [74].
Studies have also revealed that 8-iso-PGF2α stimulates
platelet shape change and reversible aggregation through
a TPR-mediated process [74]. In support of this, 8-iso-
PGF2α was found to be a potent vasoconstrictor in the rat
lung and kidney, which was specific through TPRs[81,92].
Furthermore, a TPR antagonist was shown to block 8-iso-
PGF2α-induced vasoconstriction of renal glomeruli,
carotid arteries, and vascular smooth muscle cells
[92,94,95]. Additionally, it was found that the proathero-
genic effect of 8-iso-PGF2α is mediated via TPR activation
and is secondary to the induction of specific inflamma-
tory mediators, such as sICAM-1 and MCP-1 but not ET-
1, at the site of lesion development [83]. On the other
hand, several reports disputed the notion that the stimu-
latory effects of 8-iso-PGF2α  are primarily mediated
through TPRs, adding more complexity to this issue. The
primary alternative signaling mechanism predicts the
existence of unidentified discrete isoprostane receptors in
human platelets and smooth muscle cells, the basis for
which is found in studies detailing differences between
the potencies of 8-iso-PGF2α and TPR agonists in induc-
ing DNA synthesis and MAP-kinase activation
[74,83,91,96,97]. Further complicating matters, this alter-
native proposal has also been recently disputed with sev-
eral possible explanations for the noted discrepancies
such as variations in the experimental conditions/cellular
preparations, or inherent differences in the potency of
the ligands employed [94]. In summary, there are clear
ambiguities concerning the mechanisms by which iso-
prostanes modulate cellular function.
As a distinct and further confounding layer of complex-
ity it has been recently reported that 8-iso-PGF2α signals
through both stimulatory and inhibitory pathways in
platelets and that this inhibition by 8-iso-PGF2α operates
through a cAMP-dependent mechanism (Figure 4) [70].
Additionally, reduction of isoprostane formation by vita-
min E in combination with the suppression of TXB2 bio-
synthesis (a metabolic marker of TXA2) was shown to be
more effective than the two approaches alone in experi-
mental atherosclerosis [98]. In this connection, by block-
ing TXA2 synthesis, aspirin (ASA) appears to facilitate
increased isoprostane production from AA, which in
turn, may amplify the anti-thrombotic effects of ASA
itself through a secondary inhibitory process. Taken
together, it might be predicted that a therapeutic regimen
combining ASA along with a TPR antagonist would be
more beneficial than therapy with ASA alone. Specifi-
cally, under these conditions, the isoprostane stimulatory
effects would be blocked by TPR antagonism, while its
inhibitory effects would be promoted by elevating the
levels of circulating isoprostane. Thus, specific isopros-
tane-receptor interactions may mediate agonist activa-
tion of one effector pathway, yet act as an antagonist for
an alternate pathway.
Alternative Isoprostane Signaling Pathways
Despite this body of evidence associating elevated iso-
prostane with oxidative stress and vascular disease
pathology, as well as supporting a potential role for iso-
prostanes in mediating a host of disease processes such as
apoptosis, brain cell damage, and thrombosis, their bio-
logical activity and signaling mechanisms remain poorly
understood. A major hindrance to teasing out the mecha-
nism(s) is that specific inhibition of isoprostanes is not
universally reported. Aside from prostaglandin H2-TXA2
and isoprostanes, the TPR receptors share other endoge-
nous ligands such as HETE. Moreover, other AA deriva-
tives (free radical-dependent or otherwise) may be
biologically relevant and signal through TPR, thus further
obfuscating the activity of isoprostanes on platelet biol-
ogy [99]. One of the most promising avenues for research
is thus isolating the contributions of signaling through
the TPR which is known to competently bind to isopros-
tanes. Studies report ligation of both existing membrane
and nuclear prostaglandin receptors by isoprostanes
[100,101]. However, the possibility of signaling throughTing and Khasawneh Journal of Biomedical Science 2010, 17:24
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other isoprostane receptors is raised by studies reporting
an apparent inability of isoprostanes to ligate or signal
efficiently through either TPR isoform in vitro, despite
evidence that their in vivo actions are mediated by TPR
[91,94].
One potential alternative signaling mechanism posits a
contribution by the phenomenon of GPCR heterodi-
merization, which is a result of a specific receptor having
multiple isoforms, or non-isoform receptors that can
freely dimerize with each other. Heterodimerization has
been reported to alter receptor properties such as regula-
tion and ligand binding affinity [102]. In addition, studies
indicate that GPCR heterodimers may mediate changes
in the signaling preferences/characteristics of the individ-
ual receptors [100,102-104]. An example is found in the
dimerization of the β1 and β2 adrenergic receptors,
which enhances cAMP formation in response to isoprot-
ernol and has also been implicated in regulating cardiac
contractility [105]. Similarly, dimerization of the alpha
and beta isoforms of the TPR has been shown to mediate
Figure 4 Schematic representation of a model describing the inhibitory and stimulatory signaling pathways for TPR-dependent modula-
tion of platelet activation by 8-iso-PGF2α.Ting and Khasawneh Journal of Biomedical Science 2010, 17:24
http://www.jbiomedsci.com/content/17/1/24
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alterations in both receptor regulation and signaling
[103,104]. Consistent with previous reports, 8-iso-PGF2α
stimulated TPR-mediated IP3  generation less potently
than IBOP and U46619 in cells expressing TPRα or TPRβ
individually. In contrast, while cells stably expressing
both TPRα and TPRβ, exhibited significantly enhanced IP3
generation following treatment with 8-iso-PGF2α, this
was not the case with IBOP or U46619. This finding was
not due to preferential binding to an isoform or in combi-
nation as there were no differences in the capacity for 8-
iso-PGF2α to displace the TPR antagonist SQ29,548 in
membranes generated from TPRα, TPRβ or TPRα/TPRβ
co-expressing HEK cells despite signaling more efficiently
through a TPRα/TPRβ heterodimer. However, it has been
reported that SQ29,548 does not fully occupy the binding
site for 8-iso-PGF2α  in the TPRα/TPRβ  heterodimer.
These data together indicate that heterodimerization
does not modify the well characterized TPR binding site,
but instead may create an alternative isoprostane binding
site. Additionally, the possibility exists that downstream
G  p r o t e i n  c o u p l i n g  i s  m o d i f i e d  w i t h  G P C R  h e t e r o d i -
merization. For example, if the TPRα/TPRβ heterodimer
were more efficiently coupled to Gq in co-transfected
cells it might be expected that IP3 and calcium signals
would be elevated. However, the absence of a similarly
enhanced signaling response with IBOP or U46619
stands in contradiction to this hypothesis. Finally, it's dif-
ficult to infer/interpret the biological relevance of the
impact of TPRα/TPRβ heterodimer formation on isopros-
tane biology in platelets given that platelets do not
express TPRTPRβ.
Yet another potential mechanism for isoprostane medi-
ated signaling is found at signal transduction, whereby
the response following activation of GPCR's is altered;
this is a particularly enticing avenue for future investiga-
tion since chronic disease states such as atherosclerosis
are characterized by persistent, subacute levels of dysreg-
ulation. In this connection, following their activation, dis-
sociated Gα subunits may not bind to their originally
coupled GPCR receptors. Instead, the final equilibrium of
the reassociation process for liberated Gα is determined
by the relative expression and affinity of the various acti-
vated GPCR's[106]. To illustrate, following PAR1 receptor
activation, both the level of PAR1 presentation and its Gα
affinity would decrease as PAR1 is internalized following
activation along with receptor alterations due to PAR1/
ligand interactions. Together, these effects would pro-
mote increased Gα coupling to TPRs and thus a conse-
quent shift to a higher ligand affinity state for this
receptor. Expression/affinity-mediated TPR/G-protein
coupling raises the possibility of competition for G-pro-
teins between TPRs and other GPCRs, and helping to
define the predominant signaling pathways through
which TPRs signal under different experimental condi-
tions and in different cell types. In support of this hypoth-
esis, it was found that activation of Gαi-coupled receptors
increased the potency and the efficacy of inositol phos-
phate production induced by bradykinin or UTP activa-
tion [106]. In addition, other studies demonstrated
synergistic interactions between U46619 and ADP as well
as U46619 and epinephrine [59,60,107,108].
Isoprostane Binding
Due to these sometimes confounding reports on isopros-
tane signaling, attempts have been made to elucidate the
specific segment(s) that define the receptor ligand-bind-
i n g  p o c k e t  o f  i s o p r o s t a n e s  t o  T P R ' s ,  w h i c h  w i l l  a l s o
address the question of whether isoprostanes can physi-
cally interact with TPRs or not. We, recently reported
that 8-iso-PGF2α coordinates with specific residues on
platelet TPR's and that Phe196  (Figure 4) specifically
serves as a unique TPR binding site for this ligand [70].
Furthermore, it was revealed that TPRs exhibit ligand
specificity, in both G-protein and TPR cotransfected
HEK293 cells as well as in platelets. Consistent with pre-
vious reports regarding the relative potency, the maximal
Ca2+  response observed in platelets was 3- to 4-fold
greater after stimulation with U46619 than with 8-iso-
PGF2α [42]. This is critical as the signaling in platelet acti-
vation appears to integrate at the level of elevating intrac-
ellular Ca2+. Previously it was noted that 8-iso-PGF2α
signals through both stimulatory and inhibitory pathways
in platelets and that the inhibitory effects of 8-iso-PGF2α
operated through a cAMP dependent mechanism (Figure
4). This is supported by reports that 8-iso-PGF2α interacts
with platelets at two separate binding sites [70,74,91].
One of these sites was found to mediate a small rise in
intracellular Ca2+, a concomitant increase in inositol
p h o s p h a t e s  a n d  p r o t e i n  k i n a s e  C  a c t i v a t i o n  a s  w e l l  a s
supporting irreversible platelet aggregation, when stimu-
lated by TXA2/PGH2 analogs. The other site mediates the
majority of the calcium released from intracellular stores
and platelet shape change [109,110]. Additionally, as
mentioned elsewhere, the rapid, agonist-induced phos-
phorylation of TPRα appears to involve signaling through
low affinity binding sites. This was verified in studies
using platelets pretreated with GR32191 (which blocks
the low affinity TPR sites) where it was found that neither
low concentrations of I-BOP, nor high concentrations of
agonist resulted in TPRβ phosphorylation[109].
Isoprostane in vivo Levels
In discussing isoprostanes it is important to note that iso-
prostanes can be produced in vivo at levels several orders
of magnitude higher than classical prostaglandins/throm-Ting and Khasawneh Journal of Biomedical Science 2010, 17:24
http://www.jbiomedsci.com/content/17/1/24
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boxanes, and that they remain largely stable in circulation
in comparison to ligands such as TXA2 itself [69,71].
Consequently, the biological effects of these signaling
modalities could, in theory, have a substantial systemic
impact on cellular functions along a broad temporal
range, characteristic of chronic disease states. Further-
more, it is known that the in vivo levels of isoprostanes
can be enhanced by the presence of vascular disease, thus
further associating this oxidative marker to the chronic
dysfunction characterized by oxidative stress [76,77,84].
However, one obfuscating complication remains in
deducing the role of isoprostanes in mediating platelet
activation; this derives in part from the fact that the
reported EC50 concentrations of isoprostanes required to
elicit functional responses in platelets are much higher
than their measured concentrations in the circulation,
even in syndromes of oxidant stress [74]. The highest
p l a s m a  l e v e l s  r e c o r d e d  i n  p a t i e n t s  r e m a i n  o u t s i d e  t h e
range of concentration necessary to evoke biological
responses in platelets or in other cell types. Thus, 8-iso-
PGF2α does not likely function as a conventional, circulat-
ing hormone in vivo, and even potential autocoidal func-
tions may necessitate highly concentrated forms of
delivery to local receptors. Nonetheless, it's possible that
these lipids do achieve such concentrations locally (com-
partmentalization), and hence modulate platelet function
at punctuate microenvironenments conducive for their
effect. Another possible explanation to this potential con-
flict is that incidental activation of TPR receptors by 8-iso
PGF2α  may contribute at subthreshold levels to the
adverse effects of oxidant stress in vivo as would be the
case with some of the alternative signaling modalities
described previously.
Conclusion
An alternative to the classical COX-mediated AA modifi-
cation pathway has more recently been identified, that of
chemical degradation. More specifically, free radical-
induced oxidative modification of AA, which results in
the production of a group of chemicals called isopros-
tanes [71,81]. Furthermore, isoprostanes can circulate in
vivo at concentrations orders of magnitude higher than
other AA metabolites such as TXA2 and remain much
more chemically stable (Table 1) [111-115]. This family of
lipid-mediators, particularly 8-iso-PGF2α, has been
strongly correlated with the oxidative microenviron-
ments found in various disease states. Many reports sug-
gest that isoprostanes produce their biological activity by
directly interacting with TPRs (e.g., on platelets), and a
plethora of reports indicate they are associated with
increased risk of several vascular diseases. This associa-
tion manifests in a broad range of cell types but almost all
appeared dependent on mediating TPR activation, and
secondarily, several G-proteins. Further complicating the
task of elucidating its underlying mechanism of effect,
reports have revealed that 8-iso-PGF2α signals through
both stimulatory and inhibitory pathways in platelets.
While the identity of the receptor that mediates its inhib-
itory effects remains unknown, evidence indicates that
it's coupled to Gs. And this is indicative of the continued
need for further research in this field as there are often
conflicting reports on the activity and signaling pathways
of this class of chemicals; possibly due to the subtle
nature of their contribution to platelet activation. Taken
together, this suggests the possibility that in chronic and
sustained dysregulated states as found in vascular dis-
ease, isoprostanes could possess a significant systemic
impact on cellular functions without initiating an acute
thrombotic event in the absence of other agonists and as
such remains an intriguing area of further research.
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